{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Survey Questionnaire

  1. Which of the following statements do you think most related to Indian Diabetic Phenotype (Tick any two) *

  2. As diabetes is cardio risk equivalent in general do you believe diabetes increases risk of heart failure manifold (Tick any one)? *

  3. How do you compare risk of CKD as compared to heart failure in your diabetic Patient population (Tick any one)? *

  4. According to you how much is the importance of legacy effect / or Metabolic memory in managing T2DM *

  5. What % of Your diabetes patients have high PPHG *

  6. What are the causes of High PPHG in Indians? *

  7. What % of your patients do you manage with SU based therapy? *

  8. Newly detected Diabetes patient with high PPHG what options from below you prefer *

  9. How do you compare risk of CKD as compared to Heart failure in your diabetic patient population (tick any one) *

  10. Generally diabetes being a multifactorial disease do you believe targeting multiple pathophysiologies can offer better glycemic Control? *

  11. What is the rationale of choosing Fixed dose combination in T2DM? *

  12. What according to you are the merits of FDC in Diabetes treatment (Choose any 2) *

  13. In your 100 Diabetic patients what % of patients would you have on (Sum Total of response should be 100) *

    		14.
    %

    %

    %

    %
  14. Amongst the FDC of SGLT2i+DPP4i which of the following distinguishing parameters do you find most attractive (tick any one) *

  15. Among the newer oral antidiabetic, do you consider SGLT2 inhibitors and DPP4 inhibitors as equally Efficacious? *

  16. Rank the SGLT2 inhibitors in terms of glycemic control efficacy (from 1 to 4, 1 being the highest) *

    		17.

  17. Rank the DDP4 inhibitors in terms of glycemic control efficacy (from 1 to 2, 1 being the highest) *

    		18.

  18. On patients uncontrolled on metformin, which if the following class of drug would you like to initiate first? *

  19. In diabetes patient with established ASCVD or heart failure, which class of the drug will be preferred by you as a second line treatment? *

  20. In Low-risk diabetes patients (without HF/ ASCVD or CKD), when there is a need to reduce the chances of hypoglycemia, which of the following class of drug would you prefer as a second line treatment *

  21. Among elderly diabetic patients, which of the following class of drug would you prefer taking into consideration the safety aspects *

  22. According to you, initial usage of SUs would be replaced by which class of drug? *

  23. In your 100 diabetic patients, what % of patients, you would like to recommend below class of new OAD FDC? (Sum Total of response should be 100 %) *

    24. %

    %

    %
  24. In patients with high ASCVD risk with Type 2 Diabetes, in addition to comprehensive CV risk management which class of drug you will recommend (1 = low recommendation and 5 = high recommendation) *

  25. In the patients < 55 Years of age with two or more additional risk factors (obesity, hypertension, smoking, dyslipidemia, or albuminuria) with T2DM management which class of drug you will recommend (1 = low recommendation and 5 = high recommendation) *

  26. In patients with CHF (documented HFrEF or HFpEF) with T2DM which SGLT2 you always prefer the most? *

  27. Which class of drug you will prescribe to CKD patients with T2DM? *

  28. For achievement of glycemic and weight management goals in T2DM patients which from the following you always prefer (you can select multiple options) *

  29. For achievement and maintenance of weight management Goals what is your approach in T2DM patients (you can select multiple options) *

  30. When choosing glucose lowering therapies in T2DM patients please choose your approach from the following classes of drugs with the viewpoint of efficacy for weight loss *

  31. After using the preferred class of drug selected above in T2DM patients with a goal of achievement and maintenance of glycemic and weight management, if you find A1C is still above target then what you will do to identify the barriers to goals (select any two) *

  32. In what % of your DM Patients do you recommend for CKD Profile Test *

  33. Dr according to you, Digital Therapeutics can be more beneficial in health management of diabetic patients: *

  34. Dr according to you, digital therapeutics can be more beneficial for which type of diabetes Patient *

  35. As per Diabetes Care 2023, there is impact of physical behaviors on cardiometabolic health in people with type 2 diabetes *

  36. As per Diabetes Care 2023, from the following which physical behaviour can be easily modified in the first year after getting detected with Diabetes *

  37. Systems that combine technology and online coaching can be beneficial in treating prediabetes and diabetes for some individuals – what is your opinion *

  38. As per American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm 2023 Update Prediabetes Algorithm along with lifestyle intervention, Cardiovascular risk reduction, blood pressure control, Lipid management is considered to be an essential approach – what is your opinion on this *

  39. In T2DM or Prediabetes patients with extreme high ASCVD risk, severe target organ damage, eGFR <45 will you recommend high dose statin ? *

  40. In T2D <10 years, age < 40 years, No ASCVD, no target organ damage with more than 2 risk factors will you recommend high dose statin ? *

  41. Medium intensity statin is recommended in the following patient profile of T2DM *

    		42.

  42. In T2DM with overweight or obese patients, which class of drug you will consider in the preferred category and alternative category? (tick the preferred option) *

    		43.

  43. In T2DM with Hypoglycemia risk patients, which class of drug you will consider in the preferred category and alternative category? (tick the preferred option) *

    		44.

  44. In T2DM patients with low access to medicine or cost concerns, which class of drug you will consider in the preferred category and alternative category? (tick the preferred option) *

    		45.

  45. In T2DM patients with severe hyperglycaemia, which class of drug you will consider in the preferred category and alternative category? (tick the preferred option) *

    		46.

  46. If A1c is above target and there is a compelling need to minimize hypoglycemia which combination you will prefer the most *

  47. Do you agree that more intensive preventive approaches should be considered in individuals who are at particularly high risk of progression to diabetes including individuals with BMI > 35 Kg/M2, those at higher glucose levels, and individuals with a history of gestational diabetes Mellitus? *

  48. People with diabetes can benefit from a coordinated multidisciplinary team that may include and is not limited to diabetes care and education specialists, primary care and subspecialty clinicians, nurses, registered dietitian nutritionists, exercise specialists, pharmacists, dentists, podiatrists, and mental health professionals. *

  49. According to you which of the following trials has really established the importance for DPP4i in CV Safety Outcomes (you can select multiple options) *

  50. According to you which of the following trials has really established the importance for GLP 1 RA in CV Safety Outcomes (you can select multiple options) *

  51. According to you which of the following trials has really established the importance for SGLT2i RA in CV Safety Outcomes (you can select multiple options) *

  52. In your opinion, how frequently should individuals >35 years old with normal glucose parameters test again? *

  53. As per ADA 2023 guidelines, what screening tool do you follow to identify CV Risk for T2DM Patients? *

  54. According to you, while assessing Diabetes, what other elements should also be assessed in regular clinical practice? (select all that applies) *

  55. For your T2DM Patients, which goal do you focus to achieve? *

  56. According to you, what are the benefits of continuous Glucose monitoring in Diabetes patients? *

  57. Individuals with confirmed office-based blood pressure ≥160/100 mmHg should, in addition to lifestyle therapy, have prompt initiation and timely titration of two drugs or a single-pill combination of drugs demonstrated to reduce cardiovascular events in people with diabetes. Please give your opinion. *

  58. ACE inhibitors or angiotensin receptor blockers are recommended first-line therapy for hypertension in people with diabetes and coronary artery disease. Please give your opinion. *

  59. Initial treatment for people with diabetes depends on the severity of hypertension (Those with blood pressure between 130/80 mmHg and 160/100 mmHg may begin with a single drug. For patients with blood pressure ≥160/100 mmHg, initial pharmacologic treatment with two antihypertensive medications is recommended in order to more effectively achieve adequate blood pressure control *

  60. Multiple-drug therapy is often required to achieve blood pressure targets, particularly in the setting of diabetic kidney disease *

  61. Intensify lifestyle therapy and optimize glycemic control for patients with elevated triglyceride levels (≥150 mg/dL [1.7 mmol/L]) and/or low HDL cholesterol (<40 mg/dL [1.0 mmol/L] for men, <50 mg/dL [1.3 mmol/L] for women) *

  62. In adults with diabetes, it is reasonable to obtain a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides) at the time of diagnosis, at the initial medical evaluation, and at least every 5 years thereafter in patients <40 years of age. *

  63. In younger people with longer duration of disease (such as those with youth-onset type 1 diabetes), more frequent lipid profiles may be reasonable. *

  64. For people with diabetes aged 40–75 years without atherosclerotic cardiovascular disease, use moderate-intensity statin therapy in addition to lifestyle therapy. *

  65. For people with diabetes aged 20–39 years with additional atherosclerotic cardiovascular disease risk factors, it may be reasonable to initiate statin therapy in addition to lifestyle therapy. *

  66. For people with diabetes aged 40–75 at higher cardiovascular risk, including those with one or more atherosclerotic cardiovascular disease risk factors, it is recommended to use high-intensity statin therapy to reduce LDL cholesterol by ≥50% of baseline and to target an LDL cholesterol goal of <70 mg/dL. *

  67. For people with diabetes aged 40–75 years at higher cardiovascular risk, especially those with multiple atherosclerotic cardiovascular disease risk factors and an LDL cholesterol ≥70 mg/dL, it may be reasonable to add ezetimibe or a PCSK9 inhibitor to maximum tolerated statin therapy. *

  68. In T2DM patients undergoing ACS, dual antiplatelet therapy (with low-dose aspirin and a P2Y12 inhibitor) is reasonable for a year after an acute coronary syndrome and may have benefits beyond this period. *

  69. In T2DM patients, long-term treatment with dual antiplatelet therapy should be considered for individuals with prior coronary intervention, high ischemic risk, and low bleeding risk to prevent major adverse cardiovascular events. *

  70. People with type 2 diabetes who may have had years of undiagnosed diabetes and have a significant risk of prevalent diabetic retinopathy at the time of diagnosis should have an initial dilated and comprehensive eye examination at the time of diagnosis. *

  71. All people with diabetes should be assessed for diabetic peripheral neuropathy starting at diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1 diabetes and at least annually thereafter. *

  72. Weight loss was an important factor in reducing the risk of progression of diabetes, with every kilogram of weight loss conferring a 16% reduction in risk of progression over 3.2 years. *

  73. Which patient awareness initiatives do you prefer the most for your patients? *

  74. What is your opinion on the Diabetes educator concept? How useful do you think the concept will be in achieving better management and control for your patients? *